Michael Burkes Brophy Sells 784 Shares of Natera (NASDAQ:NTRA) Stock

29 Jan 2026, 23:42 by Jessica Moore · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 784 shares of Natera stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total value of $188,575.52. Following the completion of the transaction, the chief financial officer owned 63,339 shares in the company, valued at $15,234,929.67. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $230.40, for a total value of $430,156.80.
On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The shares were sold at an average price of $237.56, for a total value of $573,232.28.
On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Stock Down 1.9%

NASDAQ NTRA traded down $4.45 during midday trading on Thursday, hitting $231.48. The company had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. The firm has a fifty day simple moving average of $235.90 and a two-hundred day simple moving average of $193.29. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The stock has a market cap of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the business earned ($0.26) earnings per share. The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. Guggenheim boosted their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. Barclays boosted their target price on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. UBS Group upped their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Stephens lifted their price objective on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Morgan Stanley increased their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Read Our Latest Analysis on Natera

Natera News Summary

Here are the key news stories impacting Natera this week:

Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

Institutional Trading of Natera

Hedge funds have recently bought and sold shares of the stock. Rakuten Investment Management Inc. bought a new position in shares of Natera in the 3rd quarter valued at $34,096,000. SWS Partners grew its position in Natera by 11.8% in the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Natera by 192.5% during the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after acquiring an additional 5,614 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after acquiring an additional 19,576 shares during the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Natera by 68.8% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock valued at $2,051,000 after purchasing an additional 4,946 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.